As of November 14, 2026, DNA X, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 5, 2026 to February 10, 2026, naming 2 appointments and 2 departures. The latest filing names Mike Mulica, appointed (Form 8-K, February 10, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like DNA X, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
DNA X, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-05 to 2026-02-10. They name 4 people, with 2 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as DNA X, Inc. files it.
Also on the record for DNA X, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 13, 2026 | Stake report, Schedule 13G/A, by LYTTON LAURENCE W | 6.8% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by LYTTON LAURENCE W | 8.1% of the class | 5%+ stakes | Source |
| February 20, 2026 | Stake report, Schedule 13D, by DNA Holdings Venture Inc. | 19.9% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by 1 Main Capital Management, LLC | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by LYTTON LAURENCE W | 9.96% of the class | 5%+ stakes | Source |
| January 23, 2026 | Stake report, Schedule 13G/A, by Streeterville Capital LLC | — | 5%+ stakes | Source |
| December 18, 2025 | Stake report, Schedule 13G, by Streeterville Capital LLC | 9.9% of the class | 5%+ stakes | Source |
| December 15, 2025 | Acquired DNA X LLC | $1.20M | Acquisition | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by 1 Main Capital Management, LLC | 8.2% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by L1 Capital Global Opportunities Master Fund, Ltd. | — | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by LYTTON LAURENCE W | 7.8% of the class | 5%+ stakes | Source |
| November 7, 2025 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs DNA X, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on DNA X, Inc. and the records around it.
DNA X, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Acquisition Dec 2025
- Who owns it
Companies that share a holder
- LYTTON LAURENCE W also filed stake reports on 28 other companies: Retension Pharmaceuticals, Inc. (Oct 2026), Rank One Computing Corp (Aug 2026), MDxHealth SA (Aug 2026)
- Streeterville Capital LLC also filed stake reports on 31 other companies: Professional Diversity Network, Inc. (Oct 2026), Solowin Holdings, Ltd. (Oct 2026), Vivos Therapeutics, Inc. (Sep 2026)
- L1 Capital Global Opportunities Master Fund, Ltd. also filed stake reports on 42 other companies: Youlife Group Inc. (Nov 2026), INLIF Ltd (Oct 2026), DarkIris Inc. (Oct 2026)
Watch DNA X, Inc.
Get an email when DNA X, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on DNA X, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on DNA X, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on DNA X, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 17 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-10 | In | 2026-02-09 | 8-K, 2026-02-10 | ||
| 2026-02-05 | Out | Director | 8-K, 2026-02-05 | ||
| 2026-02-05 | Out | 2026-01-29 | 8-K, 2026-02-05 | ||
| 2026-02-05 | In | Director | 8-K, 2026-02-05 |
Why did they leave? What the filings say
For 1 of the 2 named departures below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Peter Liu, Director (filed 2026-02-05):
Mr. Liu's resignation did not result from any disagreement with the Company.
- Charles Becher (filed 2026-02-05): the filing states no reason.
Who leads DNA X, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Peter Liu, departure reported (filed 2026-02-05). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on DNA X, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at DNA X, Inc., with the record behind each one.
Find candidates like Director at DNA X, Inc.Every change, in the filing's words
Appointed: Mike Mulica, effective 2026-02-09
Effective February 9, 2026, Mike Mulica, executive chairman of DNA X, Inc. (formerly, Sonim Technologies, Inc.), a Delaware corporation (the " Company "), was appointed as the Company's acting chief executive officer and, accordingly, was designated as the Company's principal executive officer.
- Mr. Mulica, 62, has held various roles at the Company since April 2021, most recently as its executive chairman as of October 16, 2025.
- CFO Employment Agreement On February 9, 2026, the Company and Clay Crolius, the Company's Chief Financial Officer, entered into a second amendment to Mr. Crolius's employment agreement, dated December 8, 2023 (the "CFO Amendment").
Departing: Peter Liu, Director
On January 30, 2026, Peter Liu, chief executive officer of DNA X, Inc. (formerly, Sonim Technologies, Inc.) a Delaware corporation (the " Company "), notified the Company's Board of Directors (the " Board ") that he was resigning from the office of chief executive officer of the Company and as a director on the Board, effective as of the same date.
Departing: Charles Becher, effective 2026-01-29
On February 3, 2026, Charles Becher, chief commercial officer of the Company, notified the Board that he was resigning from the office of chief commercial officer of the Company, effective as of January 29, 2026.
Appointed: Scott Walker, Director
Director Appointment On January 30, 2026, following Mr. Liu's resignation from the Board, the Board appointed Scott Walker to serve on the Board as a director.
- As required by that certain employment agreement by and between Mr. Liu and the Company, dated as of December 8, 2023, as amended by that certain first amendment to employment agreement, dated April 2, 2025 (as amended, the "Liu Employment Agreement"), the separation and release agreement entered into by Mr. Liu and the Company (the "Liu Separation and Release Agreement") provided for Mr. Liu's general release of claims against the Company.
- Additionally, the Liu Separation and Release Agreement provided that the total cash severance payment owed to Mr. Liu pursuant to the Liu Employment Agreement ($855,000) is now payable in two tranches: the first payable three days after his execution of the Liu Separation and Release Agreement and the second payable on March 15, 2026.
- The Liu Employment Agreement previously provided that the cash severance payment would be paid in one lump sum payment not more than thirty days following separation.
Tools for this story
Each opens in a new tab, filled in for DNA X, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
